Haugesund Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2004
NCT00360906
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Department of Medicine, Haugesund Hospital, N-5504 Haugesund, Norway | Department of Research and Innovation, Haugesund Hospital | Dep. of Neurology Haugesund Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

omega-3 fatty acids (Omacor) (1 trial)

Drugs in Phase 2 Trials (2)

bendamustine (treanda) (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Other Trials (1)

lansoprazole (prevacid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Hemolytic (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Hemolysis (Phase 2)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4